Get the Stockscreener App
0.8811
2.30%
0.0198
Pre-market:
.90
0.0189
+2.15%
Senti Biosciences Inc stock is traded at $0.8811, with a volume of 85,764.
It is up +2.30% in the last 24 hours and down -6.76% over the past month.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
See More
Previous Close:
$0.8613
Open:
$0.9003
24h Volume:
85,764
Relative Volume:
0.38
Market Cap:
$23.16M
Revenue:
$338.00K
Net Income/Loss:
$-47.58M
P/E Ratio:
-0.264
EPS:
-3.3374
Net Cash Flow:
$-50.28M
1W Performance:
-9.19%
1M Performance:
-6.76%
6M Performance:
-37.06%
1Y Performance:
-75.11%
1-Day Range:
$0.88
$0.925
1-Week Range:
$0.8574
$0.971
52-Week Range:
$0.797
$5.10
Senti Biosciences Inc Stock (SNTI) Company Profile
Name
Senti Biosciences Inc
Sector
Industry
Phone
(650) 239-2030
Address
2 CORPORATE DRIVE, FIRST FLOOR, SOUTH SAN FRANCISCO
Compare SNTI vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SNTI
Senti Biosciences Inc
|
0.8811 | 23.16M | 338.00K | -47.58M | -50.28M | -3.3374 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Senti Biosciences Inc Stock (SNTI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-14-25 | Initiated | H.C. Wainwright | Buy |
| Jun-06-25 | Initiated | Laidlaw | Buy |
| Oct-07-22 | Initiated | Morgan Stanley | Equal-Weight |
Senti Biosciences Inc Stock (SNTI) Latest News
Is Senti Biosciences Inc stock good for income investorsTrade Volume Summary & Smart Swing Trading Alerts - baoquankhu1.vn
Senti Biosciences to Present Clinical and Translational Data on SENTI-202 at the 11th Annual Innate Killer Conference - Bitget
Senti Bio brings early AML cell therapy data to Innate Killer meeting - Stock Titan
SNTI Stock Price, Quote & Chart | SENTI BIOSCIENCES INC (NASDAQ:SNTI) - ChartMill
Senti Biosciences Amends Lease, Restructures GeneFab Sublease - TipRanks
Senti Biosciences (NASDAQ: SNTI) halves Alameda space and resets lease with GeneFab - Stock Titan
Senti Biosciences, Inc. Enters Lease Amendment and Sublease Amendment with 1430 South Loop Owner, LLC and Genefab, LLC - marketscreener.com
Gains Report: Is Senti Biosciences Inc stock good for income investors2026 Volume Leaders & High Yield Equity Trading Tips - baoquankhu1.vn
Macro Review: Does Senti Biosciences Inc have a sustainable dividendQuarterly Growth Report & Stepwise Entry/Exit Trade Alerts - baoquankhu1.vn
Should I trade or invest in Senti Biosciences Inc2026 Pullback Review & High Yield Equity Trading Tips - baoquankhu1.vn
Senti Biosciences (SNTI) Stock Analysis Report | Financials & Insights - Benzinga España
Senti Biosciences Inc expected to post a loss of 41 cents a shareEarnings Preview - TradingView
Senti Biosciences (SNTI) officer has 10,757 shares withheld for taxes - Stock Titan
Senti Biosciences (SNTI) CEO reports 80,666-share tax withholding on RSUs - Stock Titan
Senti Biosciences Inc (SNTI) DEC/2025 Earning Prediction - Intellectia AI
Is Senti Biosciences Inc. stock a buy before product launchesWeekly Risk Report & Low Volatility Stock Recommendations - Naître et grandir
Risk Off: Is Senti Biosciences Inc stock good for income investorsJuly 2025 Levels & Growth Focused Stock Reports - baoquankhu1.vn
Senti Biosciences to Present at Leerink Partners 2026 Global Healthcare Conference - Bitget
Miami healthcare conference talk from Senti Bio CEO will be webcast live - Stock Titan
SNTI PE Ratio & Valuation, Is SNTI Overvalued - Intellectia AI
Senti Biosciences, Inc. (NASDAQ:SNTI) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
Senti Bio joins Cell & Gene Live cell therapy webinar - National Today
SNTI Should I Buy - Intellectia AI
Senti Biosciences (NASDAQ:SNTI) Shares Up 1.6% – Should You Buy? - Defense World
Senti Bio Participates in Cell & Gene Live Event on Innovative Therapies - Intellectia AI
Senti Biosciences to Showcase Gene Circuit Technology and Partnership Opportunities at TD Cowen Health Care Conference - Quiver Quantitative
Senti Bio CEO to highlight gene circuit pipeline at TD Cowen conference - Stock Titan
Senti Biosciences: A Waiting Game for Investors () - aktiencheck.de
Can Senti Biosciences Inc. sustain its profitability2025 Big Picture & Weekly High Return Stock Opportunities - mfd.ru
Senti Bio Participates in Cell & Gene Live Event Highlighting Cutting-Edge Technologies Advancing Cell Therapy Development - The Manila Times
How a cell therapy event spotlighted Senti Bio’s ‘logic-gated’ treatments - Stock Titan
Senti Biosciences reports promising phase 1 trial results - MSN
Will Senti Biosciences Inc. be affected by tariffsJuly 2025 Sector Moves & Verified Momentum Watchlists - mfd.ru
Senti Biosciences Inc. (SNTI) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Insider Trends: What are the analyst revisions for Senti Biosciences IncIs ICON stock a good investment in YEARJuly 2025 Spike Watch & Accurate Trade Setup Notifications - baoquankhu1.vn
Published on: 2026-02-16 00:06:47 - mfd.ru
Can Senti Biosciences Inc. deliver alphaTrade Signal Summary & Daily Entry Point Trade Alerts - mfd.ru
Senti Biosciences completes enrollment in Phase 1 clinical trial of Senti-202 - marketscreener.com
Senti Biosciences Completes Enrollment In Phase 1 Clinical Trial Of Senti-202 - TradingView
Senti Biosciences Completes Enrollment in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) - The Manila Times
Leukemia cell therapy SENTI-202 heads for FDA talks after early remissions - Stock Titan
Does Senti Biosciences Inc. have a sustainable dividendShare Buyback & Smart Allocation Stock Tips - mfd.ru
Retail Surge: Is FONR benefiting from interest rate changesIPO Watch & Weekly Sector Rotation Insights - baoquankhu1.vn
Gains Recap: Does Senti Biosciences Inc have a sustainable dividendMarket Trend Summary & AI Driven Price Forecasts - baoquankhu1.vn
Aug Mood: Should I trade or invest in Senti Biosciences IncInsider Selling & AI Forecast Swing Trade Picks - baoquankhu1.vn
Growth Value: What are the analyst revisions for Senti Biosciences IncIs ICON stock a good investment in YEAR2025 Top Decliners & Accurate Technical Buy Alerts - baoquankhu1.vn
Aug Movers: Does Senti Biosciences Inc have a sustainable dividend2025 Winners & Losers & Verified Momentum Stock Alerts - baoquankhu1.vn
Senti Biosciences, Inc. (NASDAQ:SNTI) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World
Senti Biosciences Selected for On-Stage Presentation at Healthcare Conference Taipei 2026 - The Manila Times
Inside Senti Bio’s 8-minute gene circuit pitch at Taipei’s 2026 healthcare conference - Stock Titan
Insider Buy: Is Senti Biosciences Inc stock good for income investorsJuly 2025 Update & Growth Oriented Trading Recommendations - baoquankhu1.vn
Senti Biosciences Inc Stock (SNTI) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):